For the January-March period

  • Net sales for the period were SEK 33.7 million (30.6).

  • Operating income (EBIT) for the period was SEK 5.8 million (4.2).

  • Operating margin for the period was 17 percent (14).

  • Earnings after tax for the period were SEK 5.5 million (1.3).

  • Earnings per share for the period, basic and diluted, were SEK 0.05 (0.01).

Significant events in the first quarter
Allenex acquired all minority holdings in the group from SSP Primers AB for SEK 20 million.
Furthermore, Allenex repaid a loan to SSP Primers AB for SEK 4 million.

CEO and President Anders Karlsson’s commentary on the first quarter 2015:
“We continued to see an increase in sales and profitability in the company during the first quarter of the year. The upswing in margins that we saw last year continued, with earnings before interest and taxes (EBIT) for the period amounting to SEK 5.8 million (17 percent). The increase in net sales for the period came mainly from the U.S., where we invested considerable resources in 2014 to build up a strong market platform. Sales and earnings also benefits from the weaker Swedish krona. The time schedule for the launch of real time PCR, a new platform for HLA typing advance according to plan and the first sales are expected during the second half of the year.”

For more information please contact:
Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail: anders.karlsson@allenex.se
Axelsson, CFO Allenex AB, and ph.: +468-508 939 72, e-mail: yvonne.axelsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on May 20, 2015, at 12.00 CET. Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 55 persons are employed in the Allenex group.


About Us

LinkMed, in collaboration with innovators, develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of eleven companies, six in biotechnology and five in medical technology. The LinkMed share is listed on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED). The company’s largest owners are FastPartner, Koncentra Holding, and the founder Ingemar Lagerlöf. See www.linkmed.se for more information.